The Insider: Meet the CEOs – 13 October

Volpara is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Through recent acquisitions, the company has grown its US market share from 5% to 34% in the past five years. Further growth is predicted, with the US expected to mandate the early screening for breast cancer – a significant tailwind for Volpara’s prospects. Volpara’s tech and services are currently used in 35 countries and the company has expanded its footprint in the US$2.8 billion lung screen market.

NSX Limited owns the National Stock Exchange of Australia (NSX) – the country’s second-largest listing stock exchange and direct competitor to the ASX. It specialises in listing growth companies and has a combined market capitalisation in excess of $2.7 billion and averages more than $8 million in raised capital per offer. NSX offers Australia’s widest range of listing options covering all market sectors with advantages such as simple rules, early-stage listing, faster listing process, and lower costs. NSX offers a collaborative and customer-focused approach with principle-based rules that reduce the work required in the IPO process.